Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11962998 | 1.00 | NOTUM (0.58) | NOTUMKDM4EALDH1A1TP53HPGD | |
| SCHEMBL853076 | 0.86 | NOTUM (0.58) | NOTUMKDM4EALDH1A1TP53HPGD | |
| Quinoline SCHEMBL27730359 | 0.83 | NOTUM (0.51) | NOTUMKDM4EALDH1A1TP53HPGD | |
| SCHEMBL5631379 | 0.81 | ALDH1A1 (0.40) | NOTUMKDM4EALDH1A1TP53HPGD | |
| SCHEMBL27984179 | 0.81 | CYP11B1 (0.45) | NOTUMKDM4EALDH1A1TP53HPGD | |
| SCHEMBL13726436 | 0.81 | HTR6 (0.39) | NOTUMKDM4EALDH1A1TP53HPGD | |
| SCHEMBL10274544 | 0.80 | NOTUM (0.59) | NOTUMKDM4EALDH1A1TP53HPGD | |
| SCHEMBL23360817 | 0.79 | NOTUM (0.58) | NOTUMKDM4EALDH1A1TP53HPGD | |
| SCHEMBL28409141 | 0.79 | NOTUM (0.58) | NOTUMKDM4EALDH1A1TP53HPGD | |
| SCHEMBL20612446 | 0.79 | NOTUM (0.58) | NOTUMKDM4EALDH1A1TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| CN-107501099-B | Modulators of ATP-binding cassette transporters | 沃泰克斯药物股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3617192-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20050282876-A1 | Ligands for Inosine-5'-monophosphate dehydrogenase; antiviral, antiinflammatory, antibiotics, transplant rejection, autoimmune disease, , antipsoriatic immunosuppressants; 3-uriedo benzyl carbamate derivatives; high potency, side effects reduction; bioavailability; antivascular hyperproliferative | VERTEX PHARMACEUTICALS INCORPORATED | 2005-12-22 | — | — | US | disclosed |
| US-6967214-B2 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-22 | — | — | US | disclosed |
| US-20030195202-A1 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-16 | — | — | US | disclosed |
| CN-1116288-C | Urea derivatives as inosine-5' -monophosphate dehydrogenase inhibitors | VERTEX PHARMA (US) | 2003-07-30 | — | — | CN | disclosed |
| US-6541496-B1 | Inosine-5'-monophosphate dehydrogenase inhibitors; merimepodib; hepatitis | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-01 | — | — | US | disclosed |
| US-6344465-B1 | INOSINE MONOPHOSPHATE DEHYDROGENASE; merimepodib; transplant rejection, autoimmune diseases, multiple sclerosis, juvenile diabetes, asthma, inflammatory diseases, lymphoma or leukemia, and hyperproliferative vascular diseases | VERTEX PHARMACEUTICALS, INCORPORATED | 2002-02-05 | — | — | US | disclosed |
| US-6054472-A | IMMUNOSUPPRESSION, TREATING TRANSPLANT REJECTION WITH MERIMEPODIB | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-04-25 | — | — | US | disclosed |
| CN-1219929-A | Urea derivatives as inosine-5' -monophosphate dehydrogenase inhibitors | VERTEX PHARMA (US) | 1999-06-16 | — | — | CN | disclosed |
| EP-0902782-A1 | UREA DERIVATIVES AS INHIBITORS OF IMPDH ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5807876-A | INOSINE-5'-MONOPHOSPATE DEHYDROGENASE; VIRAL DISEASES, CANCER, VASCULAR DISEASES; MERIMEPODIB | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195202-A1 | Inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | NOTUM 345/4885KDM4E 1407/4885ALDH1A1 37/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | NOTUM 4510/4885KDM4E 4262/4885ALDH1A1 2165/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | NOTUM 1405/4885KDM4E 1372/4885ALDH1A1 4277/4885 |
| US-20050282876-A1 | Ligands for Inosine-5'-monophosphate dehydrogenase; antiviral, antiinflammatory, antibiotics, transplant rejection, autoimmune disease, , antipsoriatic immunosuppressants; 3-uriedo benzyl carbamate derivatives; high potency, side effects reduction; bioavailability; antivascular hyperproliferative | IMPDH1, IMPDH2, UMPS | NOTUM 1277/4885KDM4E 487/4885ALDH1A1 356/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | NOTUM 1405/4885KDM4E 1372/4885ALDH1A1 4277/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | NOTUM 1405/4885KDM4E 1372/4885ALDH1A1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.